Caricamento...
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
INTRODUCTION: Renal cell carcinoma (RCC) represents 2%–3% of all cancers in adults, and its pathogenesis is mainly related to altered cellular response to hypoxia. Lenvatinib, a novel multitarget tyrosine kinase inhibitor (TKI), represents a therapeutic option, in combination with mammalian target o...
Salvato in:
| Pubblicato in: | Ther Clin Risk Manag |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5499780/ https://ncbi.nlm.nih.gov/pubmed/28721060 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S126910 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|